|国家科技期刊平台
首页|期刊导航|陕西中医|扶正解秽汤联合重组人干扰素治疗慢性宫颈炎合并高危型HPV感染临床研究

扶正解秽汤联合重组人干扰素治疗慢性宫颈炎合并高危型HPV感染临床研究OACSTPCD

Clinical effect of Fuzheng Jiehui decoction combined with recombinant human interferon in the treatment of chronic cervicitis complicated with high-risk HPV infection

中文摘要英文摘要

目的:观察扶正解秽汤联合重组人干扰素治疗慢性宫颈炎合并高危型人乳头瘤病毒(HPV)感染的临床疗效.方法:选择 160 例慢性宫颈炎合并高危型 HPV感染患者,随机分为两组,对照组(80 例)阴道内给予重组人干扰素α-2b凝胶栓治疗,观察组(80 例)在其基础上联用扶正解秽汤治疗,疗程均为 3 个月.记录两组临床疗效,比较治疗前后两组中医症状积分、宫颈炎评分和 HPV 病毒载量的变化,记录阴道分泌物恢复正常时间、宫颈糜烂面愈合时间和 HPV转阴率.比较两组细胞免疫指标与宫颈局部免疫微环境的变化.记录两组复发率与不良反应.结果:观察组与对照组临床总有效率分别为 95.00%和 76.25%,前者显著高于后者(P<0.05).与治疗前比较,两组治疗后中医症状积分、宫颈炎评分和 HPV病毒载量、血清 CD8+、阴道灌洗液白细胞介素-10(IL-10)水平显著降低(P<0.05),且观察组治疗后上述指标均低于对照组(P<0.05),两组治疗后血清 CD3+、CD4+、CD4+/CD8+比值、阴道灌洗液 sIgA、IL-2 均明显增高(P<0.05),且观察组治疗后上述指标均高于对照组(P<0.05).观察组宫颈糜烂面愈合与阴道分泌物恢复正常时间均短于对照组,HPV转阴率高于对照组(P<0.05).观察组治疗后随访6 个月的复发率低于对照组,两组不良反应发生率比较差异无统计学意义(P>0.05).结论:在重组人干扰素治疗基础上,加用扶正解秽汤能够显著改善慢性宫颈炎合并高危型 HPV感染患者症状,提高治疗疗效,降低病毒载量,提高 HPV转阴率,降低复发率,其机制可能与其调节机体细胞免疫,改善宫颈局部免疫微环境有关.

Objective:To observe the clinical efficacy of Fuzheng Jiehui decoction combined with recombinant human interferon in the treatment of chronic cervicitis complicated with high-risk human papillomavirus(HPV)in-fection.Methods:A total of 160 patients with chronic cervicitis and high-risk HPV infection were enrolled,randomly divided into two groups:the control group(80 cases)was treated with recombinant human interferonα-2b gel sup-positories intravaginally,and the observation group(80 cases)were treated with Fuzheng Jiehui decoction on the ba-sis of Fuzheng Jiehui decoction,and the course of treatment was 3 months.The clinical efficacy of the two groups was recorded,and the changes of TCM symptom score,cervicitis score and HPV viral load were compared between the two groups before and after treatment,and the time for vaginal discharge to return to normal,the healing time of cer-vical erosion surface and the rate of HPV conversion to negative were recorded.The changes of cellular immunity in-dexes and cervical local immune microenvironment were compared between the two groups.The recurrence rate and adverse reactions were recorded in the two groups.Results:The total effective rate of the observation group was 95.00%,which was significantly higher than control group(76.25%)(P<0.05).Compared with those before treatment,the TCM symptom score,cervicitis score,HPV viral load,serum CD8+ and interleukin-10(IL-10)levels of vaginal lavage fluid were significantly decreased after treatment in both groups(P<0.05),and those indexes in observation group were lower than control group(P<0.05).After treatment,and the serum CD3+,CD4+,CD4+/CD8+ ratio,sIgA in the vaginal lavage solution,and IL-2 was significantly increased(P<0.05),and those indexes in obser-vation group were higher than control group(P<0.05).The healing time of cervical erosion and vaginal discharge in observation group were shorter than control group,rate of HPV conversion was higher than control group(P<0.05).The recurrence rate of observation group was lower than control group after 6 months of treatment,and there was no significant difference in incidence of adverse reactions between the both(P>0.05).Conclusion:On the basis of recombinant human interferon therapy,the addition of Fuzheng Jiehui decoction can significantly improve the symptoms,improve the treatment efficacy,reduce the viral load,increase the rate of HPV conversion and reduce the recurrence rate in patients with chronic cervicitis and high-risk HPV infection,and the mechanism may be related to the regulation of body cellular immunity and the improvement of the local immune microenvironment of the cervix.

何锋云;欧琰;丁莺;韦笑

桂林市中西医结合医院,广西 桂林 541004桂林生命与健康职业技术学院,广西 桂林 541004

临床医学

人乳头瘤病毒扶正解秽汤重组人干扰素α-2b凝胶慢性宫颈炎免疫功能

Human papillomavirusFuzheng Jiehui decoctionRecombinant human interferonα-2b gelChron-ic cervicitisImmune function

《陕西中医》 2024 (005)

605-609 / 5

广西壮族自治区中医药管理局科研课题(GXZYC20230607)

10.3969/j.issn.1000-7369.2024.05.006

评论